SMC approval of BALVERSA® (erdafitinib) helps pave the way for first licensed bladder cancer therapy that specifically targets fibroblast growth factor receptor (FGFR3) alterations ...

Evidence-based recommendations on erdafitinib (Balversa) for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor in adults. Last reviewed: 12 ...

Erdafitinib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations in adults after at ...

Additionally, Johnson & Johnson will share progress updates on TAR-210, an erdafitinib-releasing system, and other ongoing Phase 3 trials evaluating TAR-200 against traditional therapies.

About TAR-210 TAR-210 is an investigational intravesical erdafitinib releasing system. The safety and efficacy of TAR-210 is being evaluated in a Phase 1 study (NCT05316155) in patients with ...

TAR-210 is an investigational intravesical erdafitinib releasing system. The safety and efficacy of TAR-210 is being evaluated in a Phase 1 study (NCT05316155) in patients with muscle-invasive ...

TAR-210 is a novel erdafitinib intravesical system designed to provide local, sustained release of erdafitinib within the bladder over 12-week cycles while limiting systemic toxicities.

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer. Data from a first-in-human, phase 1 trial (NCT05316155) ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.. If you have the appropriate software installed, you can download ...

Antoni Vilaseca Cabo, MD, discusses phase 1 data presented on TAR-210 for the treatment of patients with FGFR-altered high- and intermediate-risk non-muscle invasive bladder cancer.

TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder.